SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kintara Therapeutics, Inc. – ‘S-1/A’ on 7/11/19 – ‘R22’

On:  Thursday, 7/11/19, at 4:17pm ET   ·   Accession #:  1213900-19-12524   ·   File #:  333-232332

Previous ‘S-1’:  ‘S-1’ on 6/25/19   ·   Next:  ‘S-1’ on 8/1/19   ·   Latest:  ‘S-1/A’ on 10/27/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/11/19  DelMar Pharmaceuticals, Inc.      S-1/A                 71:7.9M                                   Edgar Agents LLC/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Amendment No. 1 to Form S-1                         HTML   1.11M 
 2: EX-23.1     Consent of Ernst & Young, LLP                       HTML     19K 
 9: R1          Document and Entity Information                     HTML     34K 
10: R2          Consolidated Condensed Interim Balance Sheets       HTML     90K 
11: R3          Consolidated Condensed Interim Balance Sheets       HTML     41K 
                (Parenthetical)                                                  
12: R4          Consolidated Condensed Interim Statements of Loss   HTML     63K 
                and Comprehensive Loss                                           
13: R5          Consolidated Statements of Changes in               HTML    112K 
                Stockholders' Equity                                             
14: R6          Consolidated Condensed Interim Statements of Cash   HTML     84K 
                Flows                                                            
15: R7          Going Concern, Nature of Operations, and Corporate  HTML     40K 
                History                                                          
16: R8          Significant Accounting Policies                     HTML     81K 
17: R9          Valent Technologies, LLC                            HTML     28K 
18: R10         Derivative Liability                                HTML     61K 
19: R11         Stockholders' Equity                                HTML    227K 
20: R12         Financial Instruments                               HTML     36K 
21: R13         Related Party Transactions                          HTML     22K 
22: R14         Current and Deferred Income Taxes                   HTML     37K 
23: R15         Commitments and Contingencies                       HTML     25K 
24: R16         Supplementary Statement of Cash Flows Information   HTML     31K 
25: R17         Financial Risk Management                           HTML     34K 
26: R18         Subsequent Events                                   HTML     32K 
27: R19         Significant Accounting Policies (Policies)          HTML    129K 
28: R20         Significant Accounting Policies (Tables)            HTML     25K 
29: R21         Derivative Liability (Tables)                       HTML     57K 
30: R22         Stockholders' Equity (Tables)                       HTML    202K 
31: R23         Financial Instruments (Tables)                      HTML     28K 
32: R24         Current and Deferred Income Taxes (Tables)          HTML     47K 
33: R25         Supplementary Statement of Cash Flows Information   HTML     30K 
                (Tables)                                                         
34: R26         Financial Risk Management (Tables)                  HTML     33K 
35: R27         Going Concern, Nature of Operations, and Corporate  HTML     37K 
                History (Details)                                                
36: R28         Significant Accounting Policies (Details)           HTML     30K 
37: R29         Significant Accounting Policies (Details Textual)   HTML     45K 
38: R30         Valent Technologies, LLC (Details)                  HTML     49K 
39: R31         Derivative Liability (Details)                      HTML     37K 
40: R32         Derivative Liability (Details 1)                    HTML     41K 
41: R33         Derivative Liability (Details Textual)              HTML     71K 
42: R34         Stockholders' Equity (Details)                      HTML    100K 
43: R35         Stockholders' Equity (Details 1)                    HTML     30K 
44: R36         Stockholders' Equity (Details 2)                    HTML     37K 
45: R37         Stockholders' Equity (Details 3)                    HTML     40K 
46: R38         Stockholders' Equity (Details 4)                    HTML    118K 
47: R39         Stockholders' Equity (Details 5)                    HTML     38K 
48: R40         Stockholders' Equity (Details 6)                    HTML     30K 
49: R41         Stockholders' Equity (Details 7)                    HTML     51K 
50: R42         Stockholders' Equity (Details 8)                    HTML     35K 
51: R43         Stockholders' Equity (Details 9)                    HTML     58K 
52: R44         Stockholders' Equity (Details 10)                   HTML     90K 
53: R45         Stockholders' Equity (Details 11)                   HTML     33K 
54: R46         Financial Instruments (Details)                     HTML     28K 
55: R47         Related Party Transactions (Details)                HTML     23K 
56: R48         Current and Deferred Income Taxes (Details)         HTML     47K 
57: R49         Current and Deferred Income Taxes (Details 1)       HTML     44K 
58: R50         Current and Deferred Income Taxes (Details          HTML     46K 
                Textual)                                                         
59: R51         Commitments and Contingencies (Details)             HTML     27K 
60: R52         Stockholders' Equity (Details Textual)              HTML     91K 
61: R53         Stockholders' Equity (Details Textual 1)            HTML     66K 
62: R54         Stockholders' Equity (Details Textual 2)            HTML     52K 
63: R55         Stockholders' Equity (Details Textual 3)            HTML     46K 
64: R56         Supplementary Statement of Cash Flows Information   HTML     43K 
                (Details)                                                        
65: R57         Financial Risk Management (Details)                 HTML     27K 
66: R58         Financial Risk Management (Details 1)               HTML     28K 
67: R59         Financial Risk Management (Details Textual)         HTML     48K 
68: R60         Subsequent Events (Details)                         HTML     51K 
70: XML         IDEA XML File -- Filing Summary                      XML    133K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 3: EX-101.INS  XBRL Instance -- dmpi-20190331                       XML   2.20M 
 5: EX-101.CAL  XBRL Calculations -- dmpi-20190331_cal               XML    142K 
 6: EX-101.DEF  XBRL Definitions -- dmpi-20190331_def                XML    703K 
 7: EX-101.LAB  XBRL Labels -- dmpi-20190331_lab                     XML   1.14M 
 8: EX-101.PRE  XBRL Presentations -- dmpi-20190331_pre              XML    897K 
 4: EX-101.SCH  XBRL Schema -- dmpi-20190331                         XSD    211K 
71: ZIP         XBRL Zipped Folder -- 0001213900-19-012524-xbrl      Zip    171K

‘R22’   —   Stockholders’ Equity (Tables)

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v3.19.2
Stockholders' Equity (Tables)
 9 Months Ended 12 Months Ended
Class of Stock [Line Items]    
Schedule of valuation assumptions using a Black-Scholes pricing model

   March 31,
2019		 
     
Dividend rate   0%
Volatility    70.6% to 79.1%
Risk-free rate    2.1% to 3.2%
Term - years    0.1 to 3.0 
  
Schedule of common stock issued and outstanding

   Shares of common stock
outstanding		   Common stock   Additional paid-in capital   Warrants   Accumulated deficit 
       $   $   $   $ 
Nine months ended March 31, 2019                
Balance – June 30, 2018   2,296,667    2,297    43,198,193    8,229,482    (52,441,337)
                          
Exercise and exchange of warrants   296,667    297    2,920,695    (2,210,697)   - 
Warrants issued for services   -    -    -    36,534    - 
Conversion of Series B preferred stock to common stock   10,000    10    279,041    -    - 
Series B Preferred stock dividend   14,430    14    75,463    -    (75,477)
Shares issued for services   2,269    2    10,267    -    - 
Stock option expense   -    -    355,388    -    - 
Performance stock unit expense   -    -    183,205    -    - 
Series A Preferred cash dividend   -    -    -    -    (6,267)
Loss for the period   -    -    -    -    (5,465,486)
                          
Balance – March 31, 2019   2,620,033    2,620    47,022,252    6,055,319    (57,988,567)
                          
Three months ended March 31, 2019                
Balance – December 31, 2018   2,614,342    2,614    46,851,817    6,046,587    (56,299,291)
                          
Exercise and exchange of warrants – issue costs   -    -    (16,186)   -    - 
Warrants issued for services   -    -    -    8,732    - 
Series B Preferred stock dividend   4,735    5    23,197    -    (23,202)
Shares issued for services   956    1    3,512    -    - 
Stock option expense   -    -    99,735    -    - 
Performance stock unit expense   -    -    60,177    -    - 
Series A Preferred cash dividend   -    -    -    -    (2,089)
Loss for the period   -    -    -    -    (1,663,985)
                          
Balance – March 31, 2019   2,620,033    2,620    47,022,252    6,055,319    (57,988,567)

 

   Shares of common stock
outstanding		   Common stock   Additional paid-in capital   Warrants   Accumulated deficit 
       $   $   $   $ 
Nine months ended March 31, 2018                
Balance – June 30, 2017   1,450,963    1,451    36,678,344    4,570,574    (41,118,433)
                          
Issuance of shares and warrants   800,000    800    6,191,785    2,752,751    - 
Warrants exercised for cash   25,000    25    312,475    -    - 
Warrants issued for services   -    -    -    155,204    - 
Series B Preferred stock dividend   14,881    15    142,343    -    (142,358)
Shares issued for services   407    -    4,821    -    - 
Stock option expense   -    -    430,673    -    - 
Series A Preferred cash dividend   -    -    -    -    (6,267)
Loss for the period   -    -    -    -    (8,761,061)
                          
Balance – March 31, 2018   2,291,251    2,291    43,760,441    7,478,529    (50,028,119)
                          
Three months ended March 31, 2018                
Balance – December 31, 2017   2,260,884    2,261    43,259,228    7,321,844    (47,046,347)
                          
Warrants exercised for cash   25,000    25    312,475    -    - 
Warrants issued for services   -    -    -    156,685    - 
Series B Preferred stock dividend   4,960    5    46,621    -    (46,626)
Shares issued for services   407    -    4,821    -    - 
Stock option expense   -    -    137,296    -    - 
Series A Preferred cash dividend   -    -    -    -    (2,089)
Loss for the period   -    -    -    -    (2,933,057)
                          
Balance – March 31, 2018   2,291,251    2,291    43,760,441    7,478,529    (50,028,119)
  
Employee Stock Option [Member]    
Class of Stock [Line Items]    
Schedule of outstanding under the legacy plan

   Number of
stock
options
outstanding		   Weighted
average
exercise
price		 
         
Balance – June 30, 2018   262,683    24.27 
Granted   30,000    6.10 
           
Balance – March 31, 2019   292,683    22.40 
   Number of
stock
options
outstanding		   Weighted
average
exercise
price		 
Balance – June 30, 2016   85,625    37.77 
Granted   26,460    48.22 
           
Balance – June 30, 2017   112,085    41.81 
Granted   152,698    11.35 
Forfeited   (2,100)   21.10 
           
Balance – June 30, 2018   262,683    24.27 
Summary of stock options currently outstanding and exercisable

Exercise price
$		   Number
Outstanding		   Weighted
average
remaining
contractual
life
(years)		   Number
exercisable		 
              
 6.10    30,000    9.60    6,666 
 7.00    5,451    9.23    - 
 8.70    12,000    8.59    12,000 
 9.83    83,647    9.14    23,235 
 10.60    3,600    9.03    1,200 
 11.70    30,000    3.91    30,000 
 14.98    2,500    3.17    2,500 
 20.00    13,125    2.52    13,125 
 21.10    15,900    7.51    8,700 
 29.60    4,500    5.84    4,500 
 32.00    3,000    0.17    3,000 
 37.60    4,500    6.86    4,500 
 40.00    1,250    0.50    1,250 
 41.00    4,000    7.61    3,111 
 42.00    41,250    3.81    41,250 
 44.80    3,000    6.86    3,000 
 49.50    22,460    5.31    18,458 
 53.20    8,000    7.10    7,555 
 61.60    1,500    4.00    1,500 
 92.00    3,000    4.17    3,000 
                  
      292,683         188,550 
Exercise price
$		  Number
Outstanding
at
June 30,
2018		   Weighted
average
remaining
contractual
life
(years)		   Number
exercisable
at
June 30,
2018		 
7.00   5,451    9.98    — 
8.70   12,000    9.34    7,000 
9.80   83,647    9.89    — 
10.60   3,600    9.79    — 
11.70   30,000    4.66    12,500 
15.50   2,500    3.92    2,500 
20.00   13,125    3.27    13,125 
21.10   15,900    8.26    6,300 
29.60   4,500    6.60    4,500 
32.00   3,000    0.92    3,000 
37.60   4,500    7.61    3,499 
40.00   1,250    1.25    1,250 
41.00   4,000    8.36    2,111 
42.00   41,250    4.56    41,250 
44.80   3,000    7.61    2,250 
49.50   22,460    6.07    15,182 
53.20   8,000    7.85    5,556 
61.60   1,500    4.75    1,500 
92.00   3,000    4.92    3,000 
    262,683         124,523
Schedule of valuation assumptions using a Black-Scholes pricing model  
  June 30,
2018		   June 30,
2017		 
Dividend rate   0%   0%
Volatility   72.4 to 87.1%    77.5% to 88.7% 
Risk-free rate   1.49% to 2.86%    1.00% to 1.74% 
Term – years   0.6 to 3.03    3.0 
Schedule of stock-based compensation expense

 

   Three months ended
March 31,		   Nine months ended
March 31,		 
   2019
$		   2018
$		   2019
$		   2018
$		 
                 
Research and development   12,889    9,145    64,466    130,546 
General and administrative   86,846    128,151    290,922    300,127 
                     
    99,735    137,296    355,388    430,673 
  Years ended June 30, 
   2018
$		   2017
$		 
Research and development   140,870    77,706 
General and administrative   355,055    47,041 
           
    495,925    124,747 
Summary of unvested stock options

   Number of
Options		   Weighted
average
exercise
price
$		   Weighted
average
grant date
fair value
$		 
             
Unvested at June 30, 2018   138,160    14.39    7.63 
Granted   30,000    6.10    2.56 
Vested   (64,027)   14.82    7.88 
                
Unvested at March 31, 2019   104,133    11.62    5.95 
   Number of
options		   Weighted
average
exercise
price
$		   Weighted
average
grant date
fair value
$		 
Unvested at June 30, 2016   14,102    31.71    17.25 
Granted   26,460    48.22    26.11 
Vested   (8,759)   46.81    24.83 
                
Unvested at June 30, 2017   31,803    48.09    25.74 
Granted   152,698    11.35    6.01 
Vested   (44,241)   27.81    15.02 
Forfeited   (2,100)   21.10    11.32 
                
Unvested at June 30, 2018   138,160    14.39    7.63
Schedule of warrants  
   Number of
warrants		   Amount
$		 
Balance – June 30, 2016   152,171    1,658,382 
           
Issuance of 2017 Investor Warrants(i)   207,693    2,526,336 
Issuance of 2017 Agent Warrants(i)   13,846    424,401 
Exercise of Valent Warrants(ii)   (12,500)   (89,432)
Exercise of 2015 Investor Warrants(iii)   (4,875)   (30,715)
Warrants issued for services(iv)   4,140    81,602 
           
Balance – June 30, 2017   360,475    4,570,574 
           
Issuance of 2018 Investor and 2018 Agent Warrants(v)   840,000    3,572,843 
Exercise of 2018 Investor Warrants(v)   (25,000)   (106,335)
Warrants issued for services(iv)   42,000    192,400 
           
Balance – June 30, 2018   1,217,475    8,229,482 

 

    __________
   

i)        As part of the financing completed by the Company on April 12, 2017, the Company issued the 2017 Investor Warrants and the 2017 Agent Warrants. The 2017 Investor Warrants are exercisable at $35.00 until April 19, 2022 and the 2017 Agent Warrants are exercisable at $40.60 until April 12, 2022.

ii)       The Valent warrants were exercised at $15.40 (CA$20.00) for proceeds of $192,075.

iii)      The 2015 Investor Warrants are exercisable at a price of $30.00. The warrants expire on July 31, 2020. During the year ended June 30, 2018, nil (2017 – 4,875) warrants were exercised for proceeds of $0 (2017 – $146,250).

iv)      Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below.

v)       As part of the financing completed by the Company on September 22, 2017, the Company issued the 2018 Investor Warrants and the 2018 Agent Warrants. The 2018 Investor Warrants are exercisable at $12.50 until September 22, 2022 and the 2018 Agent Warrants are exercisable at $12.50 until September 20, 2022.
Summary of changes in outstanding warrants

 

Description

  Number 
     
Balance – June 30, 2018   1,428,128 
      
Exercised for cash (i)   (197,500)
Cashless exchange (i)   (297,500)
Issued for services (ii)   14,000 
Forfeited (iii)   (2,400)
Expired (iv)   (82,225)
      
Balance - March 31, 2019   862,503 

 

i)On November 25, 2018, the Company entered into Warrant Exercise and Exchange Agreements (the "Warrant Exercise Agreements") with certain holders (the "Exercising Holders") of the 2018 Investor Warrants. Pursuant to the Warrant Exercise Agreements, in order to induce the Exercising Holders to exercise the 2018 Investor Warrants for cash, the Company agreed to reduce the exercise price from $12.50 to $4.00 per share. Pursuant to the Warrant Exercise Agreements, the Exercising Holders exercised their 2018 Investor Warrants with respect to an aggregate of 197,500 shares of common stock underlying such 2018 Investor Warrants (the "Exercised Shares"). The Company received net proceeds of $726,481, comprising aggregate gross proceeds of $790,000 net of expenses of $63,519, from the exercise of the 2018 Investor Warrants.

    

In addition, in order to further induce the Exercising Holders to exercise the 2018 Investor Warrants, the Warrant Exercise Agreements also provided for the issuance of one share of common stock to the Exercising Holders in exchange for every three shares of common stock underlying the 2018 Investor Warrants held by the Exercising Holders that are not being exercised for cash pursuant to the Warrant Exercise Agreements, if any. On November 26, 2018, the Company issued an aggregate of 99,167 shares of common stock in exchange for 297,500 2018 Investor Warrants, resulting in a 198,333 reduction in the Company's total shares of common stock outstanding on a fully-diluted basis.

 

ii)All of the warrants issued for services are exercisable at $9.00 with 12,000 expiring on September 15, 2023 and 2,000 expiring on October 11, 2021. Of the total, 12,000 vest pro rata monthly over twelve months commencing September 15, 2018 and 2,000 are fully vested as of November 11, 2018.

 

iii)Warrants issued for services exercisable at $11.70 were forfeited upon termination of the underlying agreement.

 

iv)Warrants issued for services exercisable at $70.40 expired September 12, 2018. In addition, warrants exercisable at $31.40 expired March 31, 2019.
Description  Number 
Balance – June 30, 2017   662,891 
      
Issuance of 2018 Investor Warrants   800,000 
Exercise of 2018 Investor Warrants   (25,000)
Issuance of 2018 Agent Warrants   40,000 
Warrants issued for services   42,000 
Expiry of dividend warrants   (81,250)
Expiry of 2013 Investor Warrants   (10,513)
      
Balance – June 30, 2018   1,428,128
Summary of outstanding warrants

 

 

Description

  Number   Exercise
price
$		   Expiry date
            
2018 Investor   280,000    12.50   September 22, 2022
2017 Investor   207,693    35.00   April 19, 2022
2015 Investor   97,900    30.00   July 31, 2020
2013 Placement Agent   126,250    31.40   June 30, 2019
Issued for services   26,500    30.00   July 1, 2020 to February 1, 2021
Issued for services   6,000    17.80   January 25, 2023
Issued for services   33,600    11.70   February 27, 2023
Issued for services   12,000    9.00   September 15, 2023
Issued for services   4,140    59.30   February 27, 2020
Issued for services   2,000    9.00   October 11, 2021
2018 Agent   40,000    12.50   September 20, 2022
2017 Agent   13,846    40.60   April 12, 2022
2016 Agent   10,396    40.00   May 12, 2021
2015 Agent   2,178    30.00   July 15, 2020
    862,503    24.80    

Description  Number   Exercise
price
$		   Expiry date
2018 Investor   775,000    12.50   September 22, 2022
2017 Investor   207,693    35.00   April 19, 2022
2015 Investor   97,900    30.00   July 31, 2020
2013 Investor – Amended   77,850    31.40   March 31, 2019
2013 Placement Agent   126,250    31.40   June 30, 2019
Issued for services   26,500    30.00   July 31, 2020 to February 1, 2021
Issued for services   6,000    17.80   January 25, 2023
Issued for services   36,000    11.70   February 27, 2023
Issued for services   4,375    70.40   September 12, 2018
Issued for services   4,140    59.30   February 27, 2020
2018 Agent   40,000    12.50   September 20, 2022
2017 Agent   13,846    40.60   April 12, 2022
2016 Agent   10,397    40.00   May 12, 2021 to June 8, 2021
2015 Agent   2,177    30.00   July 15, 2020
    1,428,128    20.80    
Performance Stock Units [Member]    
Class of Stock [Line Items]    
Schedule of outstanding under the legacy plan  
   Number of
PSUs
outstanding		 
Balance – June 30, 2016 and 2017   — 
Granted   140,000 
Forfeited   (20,000)
      
Balance – June 30, 2018   120,000
Schedule of valuation assumptions using a Black-Scholes pricing model

 

Dividend rate  0 %
Volatility  79.0 to 82.5 %
Risk-free rate  2.56% to 2.71 %
Term – years  1.67 to 3.24  
   June 30,
2018		 
Dividend rate   0%
Volatility   79.0 to 82.5% 
Risk-free rate   2.56% to 2.71% 
Term – years   1.67 to 3.24 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1/A’ Filing    Date    Other Filings
9/15/23
2/27/23
1/25/23
9/22/22
9/20/22
4/19/22
4/12/22
10/11/21
6/8/21
5/12/21
2/1/21
7/31/20CORRESP,  UPLOAD
7/15/20
7/1/20S-4/A
2/27/20
Filed on:7/11/19CORRESP
6/30/1910-K
3/31/1910-Q
12/31/1810-Q,  4,  8-K
11/26/18424B5,  8-K,  SC 13G
11/25/188-K
11/11/18
9/15/18
9/12/18
6/30/1810-K
3/31/1810-Q
12/31/1710-Q,  4
9/22/17424B5
6/30/1710-K,  4
4/12/17424B5,  8-K
6/30/1610-K
 List all Filings 
↑Top
Filing Submission 0001213900-19-012524   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., Apr. 28, 1:13:25.1am ET